Shanghai Pharmaceutical Accelerates Retail Restructuring
This article was originally published in PharmAsia News
As part of its restructuring, Shanghai Pharmaceutical (Group) has started consolidating since January its three major pharmaceutical retail companies - Sine Pharmacy, Leiyunshang Pharmacy and Huashi Pharmacy. As the flagship brand, Huashi Pharmacy will serve as the consolidation platform, overseeing Sine and Leiyunshang Pharmacy. Meanwhile, Shanghai Pharma is pumping assets into Huashi to increase the latter's capital. An inside source disclosed that the group's plan for the next three years focuses on accelerating the development of its direct pharmaceutical retail chain business. According to the three-step program, Shanghai Pharma will first complete integration of the group's internal retail business within 2009; it will then adopt a development model of direct selling stores, followed by ways of exploring international collaborations. (Click here for more - Chinese Language)
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.